Prophylaxis and Treatment of Cytomegalovirus Infection Postrenal Transplantation in Two Madrid Units

Transplantation Proceedings

Volumn 41, Issue 6, 2009, Pages 2416-2418

  Fernandez A ^a   Amezquita, Y ^a   Fernandez Tagarro E ^b   Escuin, F ^b   Jimenez C ^b   Sanchez Villanueva R ^b   Galeano, C ^a   Pascual, J ^a   Marcen R ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; HUMAN; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; SPAIN; VIRUS REACTIVATION;

ADULT; AGED; ANTIVIRAL AGENTS; BLOOD CHEMICAL ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; SPAIN; VIRAL LOAD; VIRUS ACTIVATION;

EID: 68949198046     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.161     Document Type: Article

References (9)

1. Guirado L., Rabella N., Díaz J.M., et al. Prophylactic and preemptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir. Nefrologia 28 (2008) 293
2. Balfour Jr. H.H., Chace B.A., Stapleton J.T., et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 320 (1989) 1381
3. Avidan Y.P., Paul M., Rahamimov R., et al. Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation. J Infect 57 (2008) 236
4. Helanterä I., Lautenschlager I., and Koskinen P. Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients. Nephrol Dial Transplant 24 (2009) 316
5. San Juan R., Aguado J.M., Lumbreras C., et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 47 (2008) 875
6. Khoury J.A., Storch G.A., Bohl D.L., et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6 (2006) 2134
7. Lopau K., Greser A., and Wanner C. Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation. Clin Transplant 21 (2007) 80
8. Kalil A.C., Levitsky J., Lyden E., et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 143 (2005) 870
9. Hodson E.M., Craig J.C., Strippoli G.F., et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 16 2 (2008) CD003774